CSPC’s B7-H3 ADC wins China breakthrough designation in platinum-resistant ovarian cancer

CSPC Pharmaceutical Group Limited (HKEX: 01093) announced that SYS6043, a humanized monoclonal antibody-drug conjugate (ADC) targeting B7-H3, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration (NMPA) for the treatment of platinum-resistant ovarian cancer, primary peritoneal carcinoma, and fallopian tube cancer as monotherapy. The designation represents the first major regulatory milestone for SYS6043, which has no prior approvals in any jurisdiction.

China’s NMPA Breakthrough Therapy Designation is functionally analogous to the US FDA designation, designed to accelerate clinical development and regulatory review for drugs targeting serious conditions with preliminary evidence of substantial clinical improvement over available therapies.

The clinical data package supporting the designation, as described by CSPC, showed that SYS6043 demonstrated more durable anti-tumor activity than both non-platinum mono-chemotherapy and mirvetuximab soravtansine (Elahere, AbbVie), reportedly doubling progression-free survival (PFS) while maintaining a manageable safety profile. The announcement did not disclose specific response rates, patient numbers, or data cutoff dates. SYS6043 has now formally entered a Phase III confirmatory trial in the platinum-resistant ovarian cancer indication.

SYS6043 targets B7-H3 (CD276), a cell surface immune checkpoint ligand broadly overexpressed across multiple solid tumor types. The antibody component binds selectively to B7-H3 on tumor cells, delivering a cytotoxic payload directly to the target. CSPC is also evaluating SYS6043 in first- and second-line small cell lung cancer and breast cancer, consistent with a broader multi-tumor ADC strategy.

The AllSci BriefSystematic R&D and deal news. Daily.

Research context

The platinum-resistant ovarian cancer space has become increasingly competitive. Merck’s pembrolizumab (Keytruda) plus paclitaxel received US FDA approval in February 2026 for PD-L1-positive patients based on the Phase III KEYNOTE-B96 trial, while mirvetuximab soravtansine holds full FDA approval for folate receptor-alpha-positive disease. Daiichi Sankyo and Merck’s raludotatug deruxtecan, a CDH6-directed ADC, received US FDA Breakthrough Therapy Designation in September 2025 for a biomarker-selected subpopulation previously treated with bevacizumab.

SYS6043’s B7-H3 target is being developed without biomarker-based patient selection in the current indication and differs mechanistically from both the folate receptor alpha and CDH6 approaches. This differentiates the molecule from Elahere, which is approved for patients with folate receptor alpha-high tumors. Cross-trial comparisons of progression-free survival should be interpreted cautiously given differences in study design and patient populations. The ongoing Phase III confirmatory trial will be the critical determinant of whether the early efficacy signal translates into regulatory approval in China and supports broader global development or partnering opportunities.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/